Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Vanda Pharmaceuticals Introduces Novel Orphan Drug VGT-1849A for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor. This investigational therapy is being developed...
Eli Lilly Announces Zepbound® as the First Prescription Medicine for Obesity-Related Sleep Apnea
Eli Lilly and Company has announced that the U.S. Food and Drug Administration has approved Zepbound® (tirzepatide) as the first prescription treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity....
Firefly Neuroscience Introduces Innovative Brain Age Biomarker for Early Alzheimer’s Detection with FDA-Cleared BNA™ Platform
Firefly Neuroscience has announced significant progress in its research on brain age assessment. The development leverages the company’s FDA-cleared BNA™ technology platform....
FDA Approves First Mesenchymal Stromal Cell (MSC) Therapy, a Major Milestone in Regenerative Medicine
The Food and Drug Administration (FDA) has approved RYONCIL®, the first mesenchymal stromal cell (MSC) therapy, for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged two months and older....
Innovent Announces Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer
Innovent Biologics has announced that the Centre for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a Breakthrough Therapy Designation (BTD) for IBI343. This is a potentially best-in-class TOPO1i anti-CLDN18.2...
Gilead's Trodelvy® Receives Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer
Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Trodelvy® (sacituzumab govitecan-hziy) in the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy....
Tolebrutinib Receives Breakthrough Therapy Designation for Non-Relapsing Secondary Progressive Multiple Sclerosis
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). ...
HUTCHMED Announces Breakthrough Therapy Designation for ORPATHYS® and TAGRISSO® Combination for the treatment of EGFR+ NSCLC
HUTCHMED has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of ORPATHYS® (savolitinib) and TAGRISSO®...
Seres Therapeutics' SER-155 Received Breakthrough Designation for Bloodstream Infections in Stem Cell Transplant Patients
Seres Therapeutics has announced that US FDA has granted Breakthrough Therapy designation to its lead investigational product, SER-155. This designation is for reducing bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) for the treatment of blood cancers....
FDA Approved Breakthrough Therapy Designation to Stoke Therapeutics' Zorevunersen for Dravet Syndrome
Stoke Therapeutics has announced that its investigational drug, zorevunersen, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). This designation is for Zorevunersen’s potential use in treating Dravet syndrome with a confirmed mutation in the SCN1A gene that is not associated with gain-of-function....
